+1,298.7%
CRDO vs MRNA
-8.5%
+1,307.3%
-62.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | +5.4% | -3.7% | +1.4% |
| 7D | -4.5% | -1.1% | -3.4% | -4.4% |
| 30D | -39.2% | +126.1% | -165.4% | -44.6% |
| 3M | -38.5% | +190.0% | -228.5% | -47.1% |
| 6M | +40.6% | +157.2% | -116.6% | +23.2% |
| YTD | +13.2% | +388.2% | -375.0% | -13.2% |
| 1Y | +2.3% | +467.0% | -464.8% | -24.6% |
| 3Y | +942.5% | +36.1% | +906.5% | +834.6% |
| All | +1,298.7% | -8.5% | +1,307.3% | +1,207.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling